NCT04191187 - Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 6, 2019

Primary Completion Date

February 11, 2024

Study Completion Date

February 14, 2024

Conditions

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaBiphenotypic Acute LeukemiaUndifferentiated LeukemiaProlymphocytic LeukemiaMyelodysplastic SyndromesChronic Myelogenous LeukemiaMyeloproliferative NeoplasmRelapsed Large Cell LymphomaMantle Cell LymphomaHodgkin LymphomaBurkitt LymphomaRelapsed T-Cell LymphomaRelapsed Chronic Lymphocytic LeukemiaRelapsed Small Lymphocytic LymphomaRelapsed Marginal B-cell LymphomaRelapsed Follicular LymphomaLymphoplasmacytic Lymphoma

Interventions

DRUG

Fludarabine

Fludarabine 30mg/m\^2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2 for a total dose of 150 mg/m\^2

DRUG

Melphalan

Melphalan 70 mg/m\^2 over 45 minutes will be administered Day -6. Melphalan dose will be calculated based on Actual Body Weight.

RADIATION

Total Body Irradiation

Total Body Irradiation (TBI) will be delivered at a dose of 200 centigray units (cGy)

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

All Listed Sponsors

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER